Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
China
· Delayed Price · Currency is CNY 11.48
+0.03 (0.26%)
Apr 30, 2026, 2:55 PM CST
SHE:301211 Revenue
Hubei Biocause Heilen Pharmaceutical had revenue of 120.16M CNY in the quarter ending March 31, 2026, with 5.00% growth. This brings the company's revenue in the last twelve months to 459.02M, up 8.71% year-over-year. In the year 2025, Hubei Biocause Heilen Pharmaceutical had annual revenue of 453.31M with 1.67% growth.
Revenue (ttm)
459.02M
Revenue Growth
+8.71%
P/S Ratio
10.42
Revenue / Employee
482.17K
Employees
952
Market Cap
4.78B
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Yabao Pharmaceutical Group | 2.20B |
| Hunan Fangsheng Pharmaceutical | 1.79B |
| Shandong Sinobioway Biomedicine | 274.81M |
| Jianmin Pharmaceutical Group | 3.35B |
| Fuan Pharmaceutical (Group) | 1.68B |
| Zhejiang Yatai Pharmaceutical | 318.16M |
| Wuhan Hiteck Biological Pharma Co.,Ltd | 543.82M |
| Zhuhai Rundu Pharmaceutical | 1.19B |